Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that Shiyao Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Jushi Biotech”), the holding subsidiary of the company, has recently initiated phase I/II clinical trials to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics and efficacy of SYS6062 in patients with advanced solid tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.